Effect of ethyl icosapentate on urinary calcium and oxalate excretion

Konya, Eiji; Tsuji, Hidenori; Umekawa, Tohru; Kurita, Takashi; Iwase, Masanori

doi:10.1046/j.1442-2042.2000.00211.x

Cited by 10 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Konya et al . also reported that some hypercalciuric calcium stone formers experienced signiﬁcant urinary calcium reduction by taking EPA 19 . Further, Yasui et al .…”

Section: Discussionmentioning

confidence: 92%

Kidney stone disease and risk factors for coronary heart disease

et al. 2005

View full text Add to dashboard Cite

Background : We conducted a case-control study to examine the impact of coronal heart disease (CHD) risk factors on calcium oxalate (CaOX) stone formation. Methods : Variables included body mass index (BMI), current alcohol use, smoking habit, hypertension, hypercholesterolemia, diabetes mellitus, and hyperuricemia. Data sufficient for analysis were obtained for 181 CaOX stone formers and 187 controls.Results : Seven of 181 stone formers (3.9%) had a history of CHD compared with none of 187 control subjects ( P = 0.007). In univariate logistic regression analysis, smoking habit (OR 4.41, 95% CI 2.85-6.84, P < 0.0001), hypertension (OR 4.24, 95% CI 2.61-6.91, P < 0.0001), hypercholesterolemia (OR 3.03, 95% CI 1.77-5.20, P < 0.0001) and BMI (OR 1.10, 95% CI 1.04-1.17, P = 0.007) reached statistical significance. In a multivariate logistic regression analysis, smoking habit (OR 4.29, 95% CI 2.68-6.86, P < 0.0001), hypertension (OR 3.57, 95% CI 2.11-6.07, P < 0.0001), and hypercholesterolemia (OR 2.74, 95% CI 1.51-5.00, P = 0.001) reached statistical significance, while BMI (OR 1.06, 95% CI 0.99-1.12, P = 0.09) did not. Conclusions : CaOX stone formers are significantly associated with several CHD risk factors, including smoking habit, hypertension, hypercholesterolemia, and obesity.

show abstract

“…Konya et al . also reported that some hypercalciuric calcium stone formers experienced signiﬁcant urinary calcium reduction by taking EPA 19 . Further, Yasui et al .…”

Section: Discussionmentioning

confidence: 92%

Kidney stone disease and risk factors for coronary heart disease

et al. 2005

View full text Add to dashboard Cite

show abstract

Omega 3 fatty acids for prevention and treatment of cardiovascular disease

Hooper

2004

Cochrane Database of Systematic Reviews

191

143

View full text Add to dashboard Cite

Background It has been suggested that omega 3 (W3, n-3 or omega-3) fats from oily fish and plants are beneficial to health. Objectives To assess whether dietary or supplemental omega 3 fatty acids alter total mortality, cardiovascular events or cancers using both RCT and cohort studies. Search methods Five databases including CENTRAL, MEDLINE and EMBASE were searched to February 2002. No language restrictions were applied. Bibliographies were checked and authors contacted. Selection criteria RCTs were included where omega 3 intake or advice was randomly allocated and unconfounded, and study duration was at least six months. Cohorts were included where a cohort was followed up for at least six months and omega 3 intake estimated. Data collection and analysis Studies were assessed for inclusion, data extracted and quality assessed independently in duplicate. Random effects meta-analysis was performed separately for RCT and cohort data. Main results Forty eight randomised controlled trials (36,913 participants) and 41 cohort analyses were included. Pooled trial results did not show a reduction in the risk of total mortality or combined cardiovascular events in those taking additional omega 3 fats (with significant statistical heterogeneity). Sensitivity analysis, retaining only studies at low risk of bias, reduced heterogeneity and again suggested no significant effect of omega 3 fats. Restricting analysis to trials increasing fish-based omega 3 fats, or those increasing short chain omega 3s, did not suggest significant effects on mortality or cardiovascular events in either group. Subgroup analysis by dietary advice or supplementation, baseline risk of CVD or omega 3 dose suggested no clear effects of these factors on primary outcomes. Neither RCTs nor cohorts suggested increased relative risk of cancers with higher omega 3 intake but estimates were imprecise so a clinically important effect could not be excluded. Authors’ conclusions It is not clear that dietary or supplemental omega 3 fats alter total mortality, combined cardiovascular events or cancers in people with, or at high risk of, cardiovascular disease or in the general population. There is no evidence we should advise people to stop taking rich sources of omega 3 fats, but further high quality trials are needed to confirm suggestions of a protective effect of omega 3 fats on cardiovascular health. There is no clear evidence that omega 3 fats differ in effectiveness according to fish or plant sources, dietary or supplemental sources, dose or presence of placebo.

show abstract